Navigation Links
Proacta Incorporated and Yakult Honsha Announce Expansion of Their Collaborative Research, Development and Commercialization Agreement
Date:8/3/2011

SAN DIEGO, Aug. 3, 2011 /PRNewswire/ -- Proacta Incorporated and Yakult Honsha Co., Ltd. (Tokyo: 2267) today announced the expansion of their Collaborative Research, Development and Commercialization Agreement to also include Proacta's PR610 compound, a hypoxia-activated pro-drug for the treatment of cancer.  Based on compelling pre-clinical data on PR610, the parties agreed to expand their existing collaboration to include PR610.  The initial agreement, signed in February 2011, for Proacta's hypoxia-activated pro-drug, PR509, granted Yakult research, development and commercialization rights to PR509 in Japan.

(Logo:  http://photos.prnewswire.com/prnh/20110803/LA45514LOGO)

(Logo:  http://photos.prnewswire.com/prnh/20110222/LA50556LOGO-b)

"Based on recent pre-clinical study results, we believe that PR610 could perform very well in the clinic," said John C. Gutheil, MD, Proacta's CEO. "We have developed a strong relationship with Yakult in the short time that we have been working together. We are delighted that Yakult is interested in PR610 and that they share our optimism regarding the potential of this molecule."

Mr. Shigeyoshi Sakamoto, Head, Pharmaceutical Division/ Managing Executive Officer, Member of the Board of Yakult, said, "We are pleased to have the opportunity to expand our collaborative research, development, and commercialization agreement with Proacta to include PR610. This molecule has shown unique promise and provides Yakult with an option on two promising molecules within Proacta's hypoxia-activated irreversible multi-kinase inhibitors portfolio for the treatment of cancer. We look forward to the continued progress and advancement of the program so that we can more quickly bring promising new treatments to patients suffering from cancer."

About PR509 and
'/>"/>

SOURCE Proacta Incorporated; Yakult Honsha Co., Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Proacta Incorporated and Yakult Honsha Announce an Agreement for the Collaborative Research, Development and Commercialization for Proactas PR509 Compound
2. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
3. Genta Incorporated Announces Third Quarter 2007 Financial Results
4. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
5. Shareholder Class Action Filed Against Vertex Pharmaceuticals Incorporated by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
6. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
7. Mars, Incorporated Commits Over $2 Million to Federal Agency for Human-Animal Interaction Research
8. Accuray Incorporated to Report Financial Results for First Quarter of Fiscal 2010
9. Accuray Incorporated to Present at 20th Annual Oppenheimer Healthcare Conference
10. ViroPharma Incorporated Reports Third Quarter 2009 Financial Results
11. Quest Diagnostics Incorporated Announces Proposed Senior Notes Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 2014 Research and Markets has ... by Equipment, by Reagent, by Application - Global Forecast ... http://photos.prnewswire.com/prnh/20130307/600769 Biopharmaceuticals are ... one of the most important and widely used techniques ... segment of the cell culture market in 2013. Growth ...
(Date:7/22/2014)... 22, 2014  Decision Resources Group finds that the market ... will remain relatively stagnant at a value of around ... percutaneous coronary intervention (PCI) volumes are growing faster in ... as the United States and ... by the increase in penetration of PCI procedures relative to ...
(Date:7/22/2014)... , July 22, 2014 Legislation backed ... Access to Local Pharmacies Act of 2014") championing ... D would undermine the availability of lower cost ... $21 billion over the next 10 years, according ... by the Pharmaceutical Care Management Association (PCMA). ...
Breaking Medicine Technology:Global Cell Culture (Bioreactor, Incubator, Centrifuge) Market - Forecast to 2018 2Global Cell Culture (Bioreactor, Incubator, Centrifuge) Market - Forecast to 2018 3The Canadian Interventional Cardiology Device Market Will Remain Relatively Stagnant Through 2022 at Around $80 Million 2The Canadian Interventional Cardiology Device Market Will Remain Relatively Stagnant Through 2022 at Around $80 Million 3New Study: H.R. 4577 to Cost $21 Billion over 10 Years 2New Study: H.R. 4577 to Cost $21 Billion over 10 Years 3
... Mylan Inc. (Nasdaq: MYL ) today ... final approval from the U.S. Food and Drug Administration ... Valacyclovir Hydrochloride Tablets, 500 mg (base) and 1000 mg ... for the herpes virus infection. The product is being ...
... National Anesthesia Services, Inc. celebrates its 21st anniversary as one of ... a locum tenens and permanent basis in hospitals, surgery centers and medical ... , , ... when we first began," said president and owner Stephen Read . ...
Cached Medicine Technology:Mylan Receives Approval for Generic Version of Valtrex® 2National Anesthesia Services, Inc. Celebrates 21 Years of Dynamic Growth and Achievement 2
(Date:7/22/2014)... on cholesterol treatment and cardiovascular risk assessment state that ... from atherosclerotic cardiovascular disease or of having a heart ... risk profile (based on age, smoking history, and cholesterol ... for when and how aggressively to treat high cholesterol ... Men,s Health , a peer-reviewed publication from Mary Ann ...
(Date:7/22/2014)... (LALCA 2014) will be held August 21 23, ... the leading cause of death not only in Latin ... previous conferences in Chile, Mexico, Argentina and Brazil, international ... in the treatment and prevention of lung cancer and ... With tobacco being the leading cause of morbi-mortality worldwide ...
(Date:7/22/2014)... The Beryl Institute announces its fifth annual ... Program. These offerings reinforce the Institute’s commitment to support ... and the need for rigorous research to understand and ... programs are intended to encourage and support research ... on the patient experience before, during and after care ...
(Date:7/22/2014)... Ticket Down is a reliable source for cheap Manchester ... MD. There has never been a better time in the ... success of the American national soccer team at the 2014 World ... that fans of the world’s sport will be able to feed ... Champions Cup. The tournament will kick off on July 24 and ...
(Date:7/22/2014)... New York, NY (PRWEB) July 22, 2014 ... Risperdal lawsuits ( http://www.risperdallawsuitcenter.com/ ) in ... his decision to deny punitive damages in cases ... (male breast growth), Bernstein Liebhard LLP reports. In ... New also denied a plaintiffs’ request to certify ...
Breaking Medicine News(10 mins):Health News:The Beryl Institute Opens Applications for 2014 Patient Experience Grant and Scholar Programs 2Health News:The Beryl Institute Opens Applications for 2014 Patient Experience Grant and Scholar Programs 3Health News:Manchester United vs. Inter Milan Tickets Fedex Field Landover: Ticket Down Slashes Ticket Prices for Inter Milan ManU International Champions Cup Match in Washington, DC 2Health News:Manchester United vs. Inter Milan Tickets Fedex Field Landover: Ticket Down Slashes Ticket Prices for Inter Milan ManU International Champions Cup Match in Washington, DC 3Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 4
... taking the contraceptive pill may find themselves less responsive to ... The study, published in the journal Human Reproduction, measured the ... - while taking and not taking the Pill. ... experienced rises and falls in their ability to sense smells, ...
... vocal cords improves voice problems in Parkinson's disease. One of ... voice quality experienced by some patients. This problem is known ... abnormalities in the area of the voice box or larynx.// ... may be hard to understand what they are saying. You ...
... might explain common digestive symptoms like gas, pain and ... the link between fructose intolerance and the symptoms of ... abdominal discomfort, bloating and changes in bowel habit. Fructose ... honey. Some people can't digest it, but the condition ...
... past evidence that hormone replacement might lower stroke risk ... does not protect women from recurrent strokes and may ... evidence that hormone replacement therapy does not have the ... doctors have long thought hormone replacement therapy might help ...
... cheese and whole milk may be at increased risk ... The rates of two types of cancer--gastric cardia and ... 30 years. To investigate potential links between these and ... dietary factors, Dr. Susan T. Mayne from Yale University ...
... who undergo surgery for breast cancer will experience ... surgery, according to new research. Dr. Erica S. ... colleagues reported the findings at the American Public ... researchers asked 266 women who had undergone breast ...
Cached Medicine News:
... Mammography has been FDA approved, and represents ... It is the first and only mammography ... - the highest available. SenoScan's larger field ... breast support is more comfortable and helps ...
... The P3000 heralds a new concept in pupillometry, ... infrared optical system developed for the P2000. ... in which we have paid particular attention to ... Our new system is extremely flexible, allowing you ...
... the most useful features is the PupilFit ... mathematical analysis of the pupil images, producing ... instantaneously. The fitted circle is shown as ... proof that the measurement ismeaningful, and not ...
... An easy-to-operate, semi-automatic urine analyzer that ensures ... your lab efficiency by reducing "hands on" ... makes it an ideal fit for work ... Criterion II Analyzer is designed for continuous ...
Medicine Products: